Back to search

Peptide record

TPDB15810

Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB15810
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
dbAMP Peptipedia CAFPdb PD_Hemolysis
standard
No
A 5-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from dbAMP, Peptipedia, CAFPdb, and other sources, with an available 3D structural model.
Sequence
RKWWK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C40H58N12O6
ANDCEQGHILMFPSTYV
KW
802.98
11.64
3
0
2
+3
4.27
-2.820
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
11000
13.70
0
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
2
K
0
M
0
F
0
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
5 reviewed residue count
C40H58N12O6 sequence-only estimate (linear, free termini)
802.98 sequence-only estimate (linear, free termini)
11.64 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
4.27 sequence-only estimate (linear, free termini)
-2.820 sequence-only estimate (linear, free termini)
Evidence Records 8 records
Evidence 1 Activity

Activity

65% Hemolysis
Toxicity
62.5 µg/mL
Hemolytic Cytotoxic
65% Hemolysis | 62.5 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. | Eur J Med Chem | 2014
Evidence 2 Activity

Activity

75% Hemolysis
Toxicity
125 µg/mL
Hemolytic Cytotoxic
75% Hemolysis | 125 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. | Eur J Med Chem | 2014
Evidence 3 Activity

Activity

85% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
85% Hemolysis | 250 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. | Eur J Med Chem | 2014
Evidence 4 Activity

Activity

3% Hemolysis
Toxicity
62.5 µg/mL
Hemolytic Cytotoxic
3% Hemolysis | 62.5 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. | Eur J Med Chem | 2014
Evidence 5 Activity

Activity

7% Hemolysis
Toxicity
125 µg/mL
Hemolytic Cytotoxic
7% Hemolysis | 125 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. | Eur J Med Chem | 2014
Evidence 6 Activity

Activity

35% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
35% Hemolysis | 250 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. | Eur J Med Chem | 2014
Evidence 7 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Eur J Med Chem. 2014 Aug 18 83:36-44.
Evidence 8 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis